Karunamoorthi Kaliyaperumal, Sabesan Shanmugavelu, Jegajeevanram Kaliyaperumal, Vijayalakshmi Jayaraman
Department of Environmental Health Science & Technology, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia.
Vector Borne Zoonotic Dis. 2013 Aug;13(8):521-44. doi: 10.1089/vbz.2011.0946. Epub 2013 May 13.
Malaria continues to be a major global public health problem with 3.3 billion people at risk in 106 endemic countries. Globally, over 1000 plants have been used as potential antimalarials in resource-poor settings due to fragile health-care systems and lack of accessibility and affordability of artemisinin-based combination therapies (ACTs). Although many believe that the use of medicinal plants that have folklore reputations for antimalarial properties is relatively safe, many herbs may be potentially toxic due to their intrinsic adverse side effects. Therefore, herbal-derived remedies require powerful and deep assessment of their pharmacological qualities to establish their mode of action, safety, quality, and efficacy. In addition, the evolution of drug resistance also demands new antimalarial agents. This can be achieved by forming a vibrant antimalarial discovery pipeline among all stakeholders, including traditional healers, ethnobotanists, scientists, entomologists, pharmacists, and research institutions, for the isolation and characterization of the bioactive compounds with the ultimate objective of finding novel modes of action antimalarial compounds that can be used to fight against drug-resistant malarial parasites.
疟疾仍然是一个重大的全球公共卫生问题,在106个疟疾流行国家中,有33亿人面临感染风险。在全球范围内,由于卫生保健系统薄弱,以及青蒿素联合疗法(ACTs)难以获取且价格昂贵,超过1000种植物已被用作资源匮乏地区的潜在抗疟药物。尽管许多人认为,使用具有抗疟功效民间声誉的药用植物相对安全,但许多草药可能因其内在的副作用而具有潜在毒性。因此,源自草药的药物需要对其药理性质进行有力而深入的评估,以确定其作用方式、安全性、质量和疗效。此外,耐药性的演变也需要新的抗疟药物。这可以通过在包括传统治疗师、民族植物学家、科学家、昆虫学家、药剂师和研究机构在内的所有利益相关者之间形成一个充满活力的抗疟药物发现流程来实现,以分离和鉴定生物活性化合物,最终目标是找到可用于对抗耐药疟原虫的具有新作用方式的抗疟化合物。